BioSpace News Archive

Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients. OSE Immunotherapeutics to receive up to €315 million in potential milestones, including a €7 million upfront, and tiered royalties on sales.

Another step in making functional diagnostics accessible to all clinicians leading to faster diagnosis of complex eye diseases.

Eurofins (Paris:ERF) subsidiary, empowerDX, today announced that it is working with Uber to offer FDA-emergency use authorized, at-home COVID-19 testing kits to consumers via on-demand delivery

Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious silver 2021 Edison Award for its VITROS® COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options.

AssureCare’s® innovative solutions empower community pharmacies to be active, reimbursed providers in a patient’s overall healthcare journey.

Immucor, Inc., a global leader in transfusion and transplantation diagnostics, announced that Palmetto MolDX has finalized a local coverage determination (LCD) for Molecular Testing for Solid Organ Allograft Rejection.

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the closing of its initial public offering of 6,900,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 900,000 additional shares of common stock, at the initial public offering price of $17.00 per share

Sarepta Therapeutics, Inc. announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation to purchase up to 2,000,000 shares of Sarepta common stock at a price of $68.50 per share in cash.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the first quarter of 2021 after market close on Monday, May 10, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT.

Dr. Laura Peek and Dr. Sean Taylor presenting novel data on SARS-CoV-2 Neutralizing Antibody Testing; Commercial Launch Planned for Summer 2021